154 related articles for article (PubMed ID: 9887490)
1. [In which marker-positive patients with germ cell tumors is residual tumor resection of value?].
Weinknecht S; Hartmann M; Weissbach L
Urologe A; 1998 Nov; 37(6):621-4. PubMed ID: 9887490
[TBL] [Abstract][Full Text] [Related]
2. Postchemotherapy Residual Tumor Resection in Patients with Elevated Tumor Markers.
Che Y; Buddensieck C; Albers P; Lusch A; Winter C; Siemer RG; Hiester A
J Urol; 2022 Mar; 207(3):617-626. PubMed ID: 34694152
[TBL] [Abstract][Full Text] [Related]
3. Significance of elevated preoperative alpha-fetoprotein in postchemotherapy residual tumor resection for the disseminated germ cell tumors.
Kobayashi T; Kawakita M; Terachi T; Habuchi T; Ogawa O; Kamoto T
J Surg Oncol; 2006 Dec; 94(7):619-23. PubMed ID: 17111392
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
[TBL] [Abstract][Full Text] [Related]
5. Correlation of serum tumor markers in advanced germ cell tumors with responses to chemotherapy and surgery.
Vugrin D; Friedman A; Whitmore WF
Cancer; 1984 Mar; 53(6):1440-5. PubMed ID: 6198071
[TBL] [Abstract][Full Text] [Related]
6. Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers.
Wood DP; Herr HW; Motzer RJ; Reuter V; Sogani PC; Morse MJ; Bosl GJ
Cancer; 1992 Nov; 70(9):2354-7. PubMed ID: 1382832
[TBL] [Abstract][Full Text] [Related]
7. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
[TBL] [Abstract][Full Text] [Related]
8. Factors that influence the results of salvage surgery in patients with chemorefractory germ cell carcinomas with elevated tumor markers.
Habuchi T; Kamoto T; Hara I; Kawai K; Nakao M; Nonomura N; Kobayashi T; Ogawa O; Kamidono S; Akaza H; Okuyama A; Kato T; Miki T
Cancer; 2003 Oct; 98(8):1635-42. PubMed ID: 14534879
[TBL] [Abstract][Full Text] [Related]
9. The case for observation of patients with clinical stage I nonseminomatous germ cell testicular tumors.
Swanson DA
Semin Urol; 1993 May; 11(2):92-8. PubMed ID: 7689741
[No Abstract] [Full Text] [Related]
10. The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3).
Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn-Cedermark G; Ståhl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Oing C; Bokemeyer C
Urol Oncol; 2019 Nov; 37(11):809.e19-809.e25. PubMed ID: 31494007
[TBL] [Abstract][Full Text] [Related]
11. Outcomes in patients with clinical stage III NSGCT who achieve complete clinical response to chemotherapy at extraretroperitoneal disease site.
Masterson TA; Carver BS; Shayegan B; Feldman DR; Motzer RJ; Bosl GJ; Sheinfeld J
Urology; 2012 May; 79(5):1079-84. PubMed ID: 22446341
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin, etoposide, bleomycin first-line therapy and early resection of residual tumor in far-advanced germinal testis cancer.
Pizzocaro G; Piva L; Salvioni R; Zanoni F; Milani A
Cancer; 1985 Nov; 56(10):2411-5. PubMed ID: 2412683
[TBL] [Abstract][Full Text] [Related]
13. [Delayed retroperitoneal lymph node excision in treatment of advanced non-seminomatous germinal cell tumors. I. Intraoperative findings in marker converted tumor].
Otto T; Goepel M; Seeber S; Rübben H
Urologe A; 1993 May; 32(3):189-93. PubMed ID: 7685554
[TBL] [Abstract][Full Text] [Related]
14. Retroperitoneal lymphadenectomy and aggressive chemotherapy in nonbulky clinical Stage II nonseminomatous germinal testis tumors.
Pizzocaro G; Zanoni F; Milani A; Piva L; Salvioni R; Pasi M; Pilotti S; Monfardini S
Cancer; 1984 Mar; 53(6):1363-8. PubMed ID: 6198070
[TBL] [Abstract][Full Text] [Related]
15. Postchemotherapy Resection of Residual Mass in Nonseminomatous Germ Cell Tumor.
Ghodoussipour S; Daneshmand S
Urol Clin North Am; 2019 Aug; 46(3):389-398. PubMed ID: 31277733
[TBL] [Abstract][Full Text] [Related]
16. [Postchemotherapy residual tumour resection in complex metastatic sites of advanced testicular germ cell tumours].
Paffenholz P; Pfister D; Heidenreich A
Urologe A; 2016 May; 55(5):632-40. PubMed ID: 26820659
[TBL] [Abstract][Full Text] [Related]
17. Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular germ cell tumors.
Hartmann JT; Schmoll HJ; Kuczyk MA; Candelaria M; Bokemeyer C
Ann Oncol; 1997 Jun; 8(6):531-8. PubMed ID: 9261521
[TBL] [Abstract][Full Text] [Related]
18. Resection of residual pulmonary masses after chemotherapy in patients with metastatic non-seminomatous germ cell tumours.
Horvath LG; McCaughan BC; Stockle M; Boyer MJ
Intern Med J; 2002 Mar; 32(3):79-83. PubMed ID: 11885847
[TBL] [Abstract][Full Text] [Related]
19. Early clinical stages of nonseminomatous testis cancer. Evaluation of the primary treatment and follow-up procedures of the SWENOTECA project.
Klepp O; Olsson AM; Ous S; Nilsson S; Høisaether PA; Tveter K
Scand J Urol Nephrol; 1991; 25(3):179-90. PubMed ID: 1658924
[TBL] [Abstract][Full Text] [Related]
20. Pattern of relapse after first line treatment of advanced stage germ-cell tumors.
Fléchon A; Culine S; Théodore C; Droz JP
Eur Urol; 2005 Dec; 48(6):957-63; discussion 963-4. PubMed ID: 16084010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
